A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis

Trial Profile

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Velusetrag (Primary)
  • Indications Diabetic gastroparesis; Gastroparesis
  • Focus Therapeutic Use
  • Acronyms DIGEST
  • Sponsors Theravance Biopharma
  • Most Recent Events

    • 02 Aug 2017 Primary endpoint (7-day mean GCSI-24H composite score (Gastroparesis Cardinal Symptoms Index) has been met.
    • 02 Aug 2017 According to Theravance Biopharma media release, company intends to present additional results from the study at upcoming medical conferences, as well as in appropriate scientific journals.
    • 02 Aug 2017 Results published in a Theravance Biopharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top